| scholarly article | Q13442814 |
| P50 | author | Cristina Miguelez | Q57975148 |
| Jose Angel Ruiz-Ortega | Q60326756 | ||
| Luisa Ugedo | Q42813298 | ||
| P2093 | author name string | Teresa Morera-Herreras | |
| Asier Aristieta | |||
| P2860 | cites work | Functional neuroanatomy of the basal ganglia as studied by dual-probe microdialysis | Q48323311 |
| Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties | Q48324018 | ||
| Effects of intrastriatal cannabinoids on rotational behavior in rats: interactions with the dopaminergic system | Q48401794 | ||
| D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease | Q48427737 | ||
| Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats | Q48485540 | ||
| Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. | Q48658239 | ||
| Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. | Q48786464 | ||
| Effects of intranigral cannabinoids on rotational behavior in rats: interactions with the dopaminergic system | Q49060851 | ||
| Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. | Q52060269 | ||
| The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway | Q70973782 | ||
| The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons | Q72302141 | ||
| Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain | Q73101567 | ||
| Unilateral dopamine denervation blocks corticostriatal LTP | Q73280384 | ||
| Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation | Q82486794 | ||
| Presynaptic Facilitation of Glutamatergic Synapses to Dopaminergic Neurons of the Rat Substantia Nigra by Endogenous Stimulation of Vanilloid Receptors | Q44418969 | ||
| Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia | Q44451116 | ||
| Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias | Q44597458 | ||
| Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo | Q44641132 | ||
| Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake. | Q44681104 | ||
| Evidence for separate neuronal mechanisms for the discriminative stimulus and catalepsy induced by Δ9-THC in the rat | Q44895997 | ||
| Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease | Q44931450 | ||
| In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity | Q45096581 | ||
| The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. | Q45108422 | ||
| Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism | Q45310537 | ||
| Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors. | Q46023513 | ||
| The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. | Q46026291 | ||
| Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. | Q46384445 | ||
| Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease | Q46443478 | ||
| High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. | Q46456086 | ||
| A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease | Q46491157 | ||
| Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. | Q46518412 | ||
| Ipsilateral turning behavior induced by unilateral microinjections of a cannabinoid into the rat subthalamic nucleus | Q47963301 | ||
| Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice | Q47994629 | ||
| Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide | Q48136699 | ||
| Motor disturbances induced by an acute dose of delta 9-tetrahydrocannabinol: possible involvement of nigrostriatal dopaminergic alterations | Q48272341 | ||
| Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action | Q48309971 | ||
| Serotonin induces long-term depression at corticostriatal synapses | Q35040674 | ||
| CB1 cannabinoid receptor signalling in Parkinson's disease | Q35054346 | ||
| Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human | Q35120095 | ||
| The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders | Q35586641 | ||
| The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats | Q35740152 | ||
| Pathological synaptic plasticity in the striatum: implications for Parkinson's disease. | Q36145938 | ||
| Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. | Q36248857 | ||
| Distribution of cannabinoid receptors in the central and peripheral nervous system. | Q36441196 | ||
| Cannabinoid CB2 receptor: a new target for controlling neural cell survival? | Q36671508 | ||
| Dopamine-mediated regulation of corticostriatal synaptic plasticity. | Q36762821 | ||
| Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. | Q36861976 | ||
| Endocannabinoids in basal ganglia circuits: implications for Parkinson disease | Q36884599 | ||
| WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. | Q37371387 | ||
| The endocannabinoid system as a target for the treatment of motor dysfunction | Q37394164 | ||
| Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum | Q37680104 | ||
| Prospects for cannabinoid therapies in basal ganglia disorders | Q37872326 | ||
| Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease | Q40358139 | ||
| Dopamine activation of endogenous cannabinoid signaling in dorsal striatum | Q41646203 | ||
| Cannabinoid receptor agonist protects cultured dopaminergic neurons from the death by the proteasomal dysfunction | Q41968489 | ||
| Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients | Q42167232 | ||
| Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons | Q42450378 | ||
| Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia | Q42486484 | ||
| Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen | Q42487505 | ||
| Co-stimulation of D(1)/D(5) and D(2) dopamine receptors leads to an increase in c-fos messenger RNA in cholinergic interneurons and a redistribution of c-fos messenger RNA in striatal projection neurons | Q42490469 | ||
| Cortical inputs and GABA interneurons imbalance projection neurons in the striatum of parkinsonian rats. | Q42493069 | ||
| Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain | Q42493166 | ||
| Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. | Q42500348 | ||
| Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 | ||
| Cortical slow oscillatory activity is reflected in the membrane potential and spike trains of striatal neurons in rats with chronic nigrostriatal lesions. | Q42508172 | ||
| Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. | Q42520647 | ||
| Involvement of subthalamic nucleus in the stimulatory effect of Delta(9)-tetrahydrocannabinol on dopaminergic neurons | Q42523185 | ||
| Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. | Q42624110 | ||
| The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats | Q42871461 | ||
| Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. | Q43611998 | ||
| Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. | Q43621342 | ||
| Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse | Q44084440 | ||
| Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. | Q44102387 | ||
| Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease | Q44237885 | ||
| Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism | Q44346123 | ||
| Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism | Q44418544 | ||
| Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain | Q22001491 | ||
| Cannabinoid receptor localization in brain | Q24558751 | ||
| GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current | Q24653442 | ||
| The orphan receptor GPR55 is a novel cannabinoid receptor | Q24670137 | ||
| Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets | Q28203208 | ||
| Structure of a cannabinoid receptor and functional expression of the cloned cDNA | Q28240076 | ||
| Identification of GPR55 as a lysophosphatidylinositol receptor | Q28244299 | ||
| N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors | Q28244889 | ||
| Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis | Q28268078 | ||
| Identification and functional characterization of brainstem cannabinoid CB2 receptors | Q28276972 | ||
| Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors | Q28292914 | ||
| Molecular characterization of a peripheral receptor for cannabinoids | Q28298338 | ||
| Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice | Q28343324 | ||
| Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata | Q28377147 | ||
| Cannabinoid CB(1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice | Q28585963 | ||
| Isolation and structure of a brain constituent that binds to the cannabinoid receptor | Q29547476 | ||
| Formation and inactivation of endogenous cannabinoid anandamide in central neurons | Q29620558 | ||
| Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain | Q30047898 | ||
| Dichotomous dopaminergic control of striatal synaptic plasticity | Q30493521 | ||
| CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum | Q31817073 | ||
| Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? | Q33211909 | ||
| Pharmacological characterization of GPR55, a putative cannabinoid receptor | Q33869340 | ||
| Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens | Q33904968 | ||
| Dopamine-mediated regulation of striatal neuronal and network interactions | Q34070883 | ||
| CB2: a cannabinoid receptor with an identity crisis | Q34098185 | ||
| Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature | Q34273182 | ||
| Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study | Q34358022 | ||
| Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra | Q34421920 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| Dopamine-dependent synaptic plasticity in striatum during in vivo development | Q34658296 | ||
| Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system | Q34745063 | ||
| Cannabinoid receptors: where they are and what they do. | Q34772274 | ||
| Trpv1 reporter mice reveal highly restricted brain distribution and functional expression in arteriolar smooth muscle cells | Q34929688 | ||
| P921 | main subject | dopamine | Q170304 |
| endocannabinoids | Q10483908 | ||
| P304 | page(s) | 110 | |
| P577 | publication date | 2012-06-12 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | Endocannabinoid modulation of dopaminergic motor circuits | |
| P478 | volume | 3 |
| Q37512670 | Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. |
| Q30361677 | Mechanisms for alternative treatments in Parkinson's disease: acupuncture, tai chi, and other treatments. |
| Q30818488 | Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid. |
| Q35014951 | Temporal changes of CB1 cannabinoid receptor in the basal ganglia as a possible structure-specific plasticity process in 6-OHDA lesioned rats. |
| Q35171113 | The therapeutic potential of cannabinoids for movement disorders |
Search more.